Ticker brief
TGTX TG THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$54.17
1 day
+1.9%
14 days
-2.2%
mkt cap
$8.2B
signals 14d
24
authors 14d
10
crowd 14d
-0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 60% mid · 55 pctile own 1y | IV/HV 1.43× |
| Skew — 25Δ RR 30d | +0.002 67 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +1.90 normal | 5-session Δ +0.09 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-08-05 (z=2.7) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 8 | +0.31 |
| @YYDSxjm | B | -0.25 | 4 | +0.74 |
| @fj_nextstage | C | -2.23 | 3 | +0.07 |
| @BiopharmIQ | B | · | 2 | +0.00 |
| @OzmosiHealth | C | · | 2 | +0.00 |
| @MartyChargin | C | -0.56 | 1 | +0.40 |
| @RevShark | B | +1.92 | 1 | -0.55 |
| @gmorton512 | C | +0.02 | 1 | -0.75 |
| @TheNewMoney_app | C | · | 1 | -0.35 |
| @bullishchart | C | -1.21 | 1 | +0.45 |
Recent signals24of 24 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @semodough | +0.00 | The tweet gives the October 21 abstract date and October 23 presentation time. | +0.4% | tweet ↗ |
| 2026-10-15 | @YYDSxjm | +0.95 | Lays out successive catalysts and price objectives from 60 through a possible 110 buyout. | -3.3% | tweet ↗ |
| 2026-10-14 | @YYDSxjm | +0.70 | Urges existing TGTX longs to hold ahead of trial completion and expected results. | -0.4% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 3 ublituximab multiple-sclerosis results. | -0.3% | tweet ↗ |
| 2026-10-12 | @YYDSxjm | +0.70 | Says the bullish TGTX thesis is confirmed on efficacy, safety, speed and cost. | -2.0% | tweet ↗ |
| 2026-10-12 | @BiopharmIQ | +0.00 | Catalogs opening price moves tied to biotech data releases. | -2.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.60 | Says five-year data show Briumvi outperforming Ocrevus and ofatumumab. | -2.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.65 | Five-year comparison associates Briumvi with lower progression and relapse risk than two rivals. | -2.0% | tweet ↗ |
| 2026-10-12 | @semodough | +0.30 | TG Therapeutics announced publication of a five-year comparative Briumvi analysis. | -2.0% | tweet ↗ |
| 2026-10-10 | @bullishchart | +0.45 | Reports a Wall Street price-target hike alongside a new trial and bullish 20-day moving-average cross. | -2.2% | tweet ↗ |
| 2026-10-09 | @fj_nextstage | -0.25 | Reports the largest upward and downward IBD50 ranking changes, capped to six leading movers. | -2.2% | tweet ↗ |
| 2026-10-09 | @fj_nextstage | +0.35 | Tracks IBD50 additions and deletions with technical reasons; tickers capped at six. | -2.2% | tweet ↗ |
| 2026-10-09 | @semodough | +0.30 | Views BofA's TGTX preview as unusually balanced and notes a clean Phase 3 could improve its stance. | -2.2% | tweet ↗ |
| 2026-10-09 | @OzmosiHealth | +0.00 | TG Therapeutics scheduled presentation of Phase 3 MS results for Ublituximab on Oct. 22. | -2.2% | tweet ↗ |
| 2026-10-08 | @semodough | +0.65 | Seven-year UBL data show consistent efficacy, disease control, disability improvement, and safety. | +1.6% | tweet ↗ |
| 2026-10-08 | @BiopharmIQ | +0.00 | Biotech news roundup reports concrete clinical, regulatory and corporate events. | +1.6% | tweet ↗ |
| 2026-10-08 | @semodough | +0.00 | Provides the date and time for initial Phase 1 azercel clinical data at ACTRIMS26. | +1.6% | tweet ↗ |
| 2026-10-08 | @semodough | +0.00 | Flags an October 23 late-breaking presentation of initial Phase 1 azercel results. | +1.6% | tweet ↗ |
| 2026-10-07 | @YYDSxjm | +0.60 | Expects positive MS clinical data at ACTRIMS and highlights multiple upcoming presentations. | +2.3% | tweet ↗ |
| 2026-10-07 | @TheNewMoney_app | -0.35 | Reports a $150,000 purchase of TGTX 40 puts expiring January 19, 2029. | +2.3% | tweet ↗ |
| 2026-10-07 | @gmorton512 | -0.75 | Describes narrow power-sector leadership, biotech damage and cautious incremental buying at valid entries. | +2.3% | tweet ↗ |
| 2026-10-06 | @RevShark | -0.55 | Reports widespread biotech breakdowns across IBB and several constituent names. | +3.8% | tweet ↗ |
| 2026-10-04 | @MartyChargin | +0.40 | Highlights a pullback to the 50-day average and multiple year-end catalysts. | -0.2% | tweet ↗ |
| 2026-10-02 | @fj_nextstage | +0.10 | The author catalogs IBD50 additions and deletions and criticizes FFTY as an invalid test of CAN-SLIM. | -0.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.